01—Abstract
Summary
Summary of the 10-K filed September 30, 2002. Cited figures are marked; the original filing is the authoritative source.
Cardinal Health, Inc. (CAH) demonstrated robust growth in fiscal year 2002, with a 15% increase in total operating revenue, reaching $44.4 billiona.
This growth was driven by strong performance across its four key segments: Pharmaceutical Distribution and Provider Services, Medical-Surgical Products and Services, Pharmaceutical Technologies and Services, and Automation and Information Services. The company continued its acquisitive growth strategy, completing several acquisitions that expanded its service offerings and market reach. Despite overall revenue growth, the company experienced a slight decrease in gross margin percentage due to a higher mix of lower-margin pharmaceutical distribution revenue and competitive pricing pressures in its medical-surgical segment.
Significant special charges related to integration and restructuring activities impacted net earnings, though the company maintained solid operating earnings. Cardinal Health remains a dominant player in the healthcare supply chain, well-positioned for future growth through strategic acquisitions and operational efficiencies.
02—Key points
Key Highlights
- Total operating revenue increased by 15% to $44.4 billion in fiscal year 2002, driven by strong performance across all four business segments.
- The company continued its aggressive acquisition strategy, completing several acquisitions in fiscal 2002, notably Magellan Laboratories Incorporated and Boron, LePore & Associates, Inc., to enhance its Pharmaceutical Technologies and Services segment.
- Despite revenue growth, the overall gross margin decreased slightly to 9.1% from 9.3% in the prior year, primarily due to a shift towards lower-margin pharmaceutical distribution revenue and competitive pressures.
- Selling, general, and administrative expenses as a percentage of operating revenue decreased in fiscal 2002 due to economies of scale and productivity gains, further aided by the cessation of goodwill amortization.
- The company incurred significant special charges totaling $138.6 million in fiscal 2002, primarily related to merger integration, distribution center consolidations, and other restructuring activities, which reduced net earnings.
- Cardinal Health's market capitalization as of September 9, 2002, was approximately $28.2 billion, with 444.6 million common shares outstanding.
- The company anticipates continued dividend payments, with a quarterly cash dividend of $0.025 per common share paid during fiscal year 2002.
03—Questions
Frequently Asked Questions
What was Cardinal Health's revenue performance in fiscal year 2002?
Cardinal Health reported a 15% increase in total operating revenue for fiscal year 2002, reaching $44.4 billion. This growth was broad-based, with contributions from all four of its operating segments.
How did the company's acquisition strategy impact its results?
The company continued to pursue a vigorous acquisition strategy, completing several acquisitions in fiscal 2002 to expand its capabilities, particularly within the Pharmaceutical Technologies and Services segment. These acquisitions, while contributing to growth, also incurred integration costs, reflected in the special charges.
What is the outlook for Cardinal Health's profitability given the gross margin trends and special charges?
While the company experienced a slight decline in gross margin percentage due to business mix and competitive pressures, it improved operating efficiency by reducing SG&A expenses as a percentage of revenue. Significant special charges in fiscal 2002 impacted net earnings, but the company's core operations generated solid operating earnings. The company anticipates continued dividend payments, signaling confidence in its ongoing financial health.
What are the main risks facing Cardinal Health as outlined in the filing?
Key risks include changes in the U.S. healthcare environment such as evolving government reimbursement policies and managed care trends, additional regulatory risks, and risks generally associated with the company's acquisition strategy and the complexity of integrating acquired businesses. Fluctuations in large customer purchases and supplier relationships are also mentioned as potential risk factors.
04—Continue